As depicted in Fig 4, treatment with SGLT2 inhibitors reduced the hazard of the primary composite cardio-renal outcome across almost all prespecified strata, whereas in participants without baseline renal disease the hazard ratio crossed unity and numerically favoured biguanide therapy [23,24]. This evidence concerns the gene SLC5A2 and kidney disorder.